BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/18/2025 8:12:13 AM | Browse: 57 | Download: 130
 |
Received |
|
2024-08-31 07:10 |
|
Peer-Review Started |
|
2024-08-31 07:10 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-10-23 01:57 |
|
Revised |
|
2024-10-30 14:12 |
|
Second Decision |
|
2024-12-02 02:38 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-12-02 08:21 |
|
Articles in Press |
|
2024-12-02 08:21 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-12-17 07:24 |
|
Publish the Manuscript Online |
|
2025-01-18 08:12 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Case Report |
| Article Title |
Anti-programmed death-1 immunotherapy-promising treatment for metastatic colorectal cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Tian-Hao Guo, Sheng-Wei Hong, Wen-Jian Zhu, Yi-Fan Hui, Wen-Li Qiu, Yan Wu, Xuan Li, Fei Ke, Liu Li and Hai-Bo Cheng |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Key R and D Program of China |
No. 2022YFC3500200 |
| National Key R and D Program of China |
No. 2022YFC3500204 |
| Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine |
No. ZYYCXTD-C-202208 |
| NATCM’s Project of High-level Construction of Key TCM Disciplines |
No. [2023]85 |
| Qing Lan Project of Jiangsu Higher Education Institutions |
No. [2023]27 |
| Jiangsu Postgraduate Practice Innovation Plan |
No. SJCX22_0706 |
| General project of Universities’ philosophy and social science in Jiangsu Province |
No. 2024SJYB0564 |
|
| Corresponding Author |
Hai-Bo Cheng, Chief Physician, PhD, Professor, The First Clinical Medical College, Nanjing University of Chinese Medicine, No. 138 Xianlin Road, Nanjing 210023, Jiangsu Province, China. haibocheng@njucm.edu.cn |
| Key Words |
Colorectal cancer; Colorectal liver metastasis; Drug resistance; Immunotherapy; Anti-programmed death-1; Case report |
| Core Tip |
The patient described in this report has survived for more than 6 years since the diagnosis of colorectal liver metastasis. The patient achieved clinical remission after anti-programmed death-1 (PD-1) immunotherapy when different systemic therapies failed. This case demonstrates the promising potential of holistic integrative medicine, combining anti-PD-1 immunotherapy with complementary and alternative treatments, for managing advanced malignancies amid drug resistance and disease progression. |
| Publish Date |
2025-01-18 08:12 |
| Citation |
<p>Guo TH, Hong SW, Zhu WJ, Hui YF, Qiu WL, Wu Y, Li X, Ke F, Li L, Cheng HB. Anti-programmed death-1 immunotherapy-promising treatment for metastatic colorectal cancer: A case report. <i>World J Gastrointest Oncol</i> 2025; 17(2): 100954</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i2/100954.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i2.100954 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
